Search results for CXCR3 antibody

Anti-CD183/CXCR3 Antibody (R3L90), AntibodySystem, RHE67902

Anti-CD183/CXCR3 Antibody (R3L91), AntibodySystem, RHE67903

Anti-CXCR3 antibody - C-terminal, Abcam, AB181013

Anti-CXCR3 antibody [EPR23845-44], Abcam, AB259865

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CXCR3 antibody [EPR25373-32], Abcam, AB288437

What is this antibody validated in? Anti-CXCR3 antibody [EPR25373-32] (ab288437) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC-P) in Human, Mouse, Rat samples. What is the molecular weight of CXCR3? Anti-CXCR3 [EPR25373-32] (ab288437) specifically detects a band for CXCR3 (UniProt: P49682) at a molecular weight of 40kDa. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Other related products We have a range of other formats of antibody clone [EPR25373-32] also available for your convenience: ab288437, Carrier free - ab288446 , PE - ab317883 , APC - ab317919 , Alexa Fluor® 488 - ab317959 , Alexa Fluor® 594 - ab318000 , Alexa Fluor® 555 - ab318042 , Alexa Fluor® 647 - ab318084 , Alexa Fluor® 750 - ab321546 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CXCR3 antibody [EPR27377-504], Abcam, AB324731

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CXCR3 antibody [MM0223-7K22], Abcam, AB89255

Anti-CD183/CXCR3 Antibody (R1X51), AntibodySystem, RHE67901

Anti-Human CD183/CXCR3 Antibody (5H7), ProteoGenix, PTX27157

PE Anti-CXCR3 antibody [EPR25373-32], Abcam, AB317883

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.